Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
+$1.25B |
| 2 |
Charles Schwab
SCHW
|
+$588M |
| 3 |
Microsoft
MSFT
|
+$511M |
| 4 |
Invesco WilderHill Clean Energy ETF
PBW
|
+$461M |
| 5 |
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
|
+$434M |
Top Sells
| 1 |
Tesla
TSLA
|
+$1.15B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.12B |
| 3 |
CD
Chindata Group Holdings Limited American Depositary Shares
CD
|
+$652M |
| 4 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$428M |
| 5 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$395M |
Sector Composition
| 1 | Technology | 18.42% |
| 2 | Consumer Discretionary | 11.17% |
| 3 | Financials | 10.9% |
| 4 | Healthcare | 8.48% |
| 5 | Communication Services | 7.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3501
Voyager Therapeutics
VYGR
$227M
| $120K | ﹤0.01% |
16,833
+7,478
| +80% | +$53.3K |
|
|
AGEN
3502
Agenus
AGEN
$140M
| $119K | ﹤0.01% |
1,904
+1,145
| +151% | +$71.6K |
|
3503
Byline Bancorp
BY
$1.33B
| $119K | ﹤0.01% |
7,719
+6,293
| +441% | +$97K |
|
3504
ATN International
ATNI
$237M
| $118K | ﹤0.01% |
2,815
+1,884
| +202% | +$79K |
|
|
CLLS
3505
Cellectis
CLLS
$309M
| $118K | ﹤0.01% |
4,374
-3,075
| -41% | -$83K |
|
3506
iShares MSCI Germany ETF
EWG
$2.4B
| $118K | ﹤0.01% |
3,717
-248,798
| -99% | -$7.9M |
|
3507
JPMorgan US Momentum Factor ETF
JMOM
$1.67B
| $118K | ﹤0.01% |
3,047
+1,855
| +156% | +$71.8K |
|
3508
Quince Therapeutics
QNCX
$85.9M
| $118K | ﹤0.01% |
4,240
+3,331
| +366% | +$92.7K |
|
|
SCPL
3509
DELISTED
SciPlay Corporation Class A Common Stock
SCPL
| $118K | ﹤0.01% |
+8,484
| New | +$118K |
|
|
CEL
3510
DELISTED
Cellcom Israel, Ltd.
CEL
| $118K | ﹤0.01% |
23,989
-61,152
| -72% | -$301K |
|
3511
VanEck Biotech ETF
BBH
$347M
| $117K | ﹤0.01% |
693
+4
| +0.6% | +$675 |
|
3512
Banco de Chile
BCH
$15.2B
| $117K | ﹤0.01% |
5,754
+561
| +11% | +$11.4K |
|
3513
BlackRock Resources & Commodities Strategy Trust
BCX
$768M
| $117K | ﹤0.01% |
15,819
+2,152
| +16% | +$15.9K |
|
3514
Cass Information Systems
CASS
$560M
| $117K | ﹤0.01% |
2,997
-16,568
| -85% | -$647K |
|
3515
Crawford & Co Class A
CRD.A
$524M
| $117K | ﹤0.01% |
15,811
+1,801
| +13% | +$13.3K |
|
3516
Haverty Furniture Companies
HVT
$372M
| $117K | ﹤0.01% |
4,212
+3,031
| +257% | +$84.2K |
|
3517
Nuveen Taxable Municipal Income Fund
NBB
$475M
| $117K | ﹤0.01% |
4,943
| – | – |
|
3518
iShares US Utilities ETF
IDU
$1.61B
| $116K | ﹤0.01% |
1,490
-3,210
| -68% | -$250K |
|
3519
i3 Verticals
IIIV
$733M
| $116K | ﹤0.01% |
3,498
+2,787
| +392% | +$92.4K |
|
3520
Nuveen New York Municipal Value Fund
NNY
$157M
| $116K | ﹤0.01% |
11,638
+6
| +0.1% | +$60 |
|
3521
Nurix Therapeutics
NRIX
$669M
| $116K | ﹤0.01% |
3,514
+2,981
| +559% | +$98.4K |
|
|
MRNS
3522
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $116K | ﹤0.01% |
9,521
+8,320
| +693% | +$101K |
|
|
CLVS
3523
DELISTED
Clovis Oncology, Inc.
CLVS
| $116K | ﹤0.01% |
24,104
-3,642
| -13% | -$17.5K |
|
3524
AudioCodes
AUDC
$289M
| $115K | ﹤0.01% |
+4,188
| New | +$115K |
|
3525
Atea Pharmaceuticals
AVIR
$243M
| $115K | ﹤0.01% |
+2,747
| New | +$115K |
|